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OBJECTIVES: To conduct a study to assess value perceptions
and the evidence needs for key stakeholders of medical product
manufacturers, including payers and employers. This study was
a structured, qualitative assessment of inﬂuential U.S. health
plans and companies. METHODS: Telephone survey interviews
were used to collect data from ﬁfteen private U.S. payer re-
presentatives and payer-related experts. Phone and in-person
interviews were conducted with twenty-six U.S. employer 
representatives. Working behavioral assumptions were con-
structed for the payer and employer groups, and stakeholder-
speciﬁc discussion guides were used to facilitate the survey 
interviews. RESULTS: The top payer ﬁndings suggest that health
plans are most interested in clinical safety, efﬁcacy, and effec-
tiveness evidence. Payers’ demands are increasing for more 
clinical utility and clinical performance studies providing 
comparative information for medical products. Cost and cost-
effectiveness were identiﬁed as important but secondary con-
siderations for coverage and reimbursement decisions. The
employers surveyed exhibited substantial diversity in their
approach to providing health care beneﬁts for employees. The
majority of employers and payers reported that consumer-
directed health care (CDHC) plans are increasing in scope and
will play a larger role moving forward. Most reported that the
effects of CDHC on costs and long-term health outcomes are
unclear. Recent trends associated with health care costs increas-
ing faster than inﬂation contribute to employers’ difﬁculty with
deﬁning “value in health care” and to their challenges associated
with evaluating return on investment for health care expendi-
tures. CONCLUSION: U.S. employers and payers are struggling
with clearly deﬁning the concept of medical product value.
Payers rely on phase III randomized controlled trials as their
primary evidence source for covering medical products, yet
request additional post-marketing comparative studies. Employ-
ers are largely engaged in cost-shifting to employees and are
trying to select younger and healthier workforces to reduce their
health care expenditures.
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OBJECTIVES: The FDA Modernization Act of 1997 created a
six-month of market exclusivity extension in exchange for phar-
maceutical companies’ pediatric studies for the drugs of poten-
tial beneﬁts to the pediatric population. This study examines
how the voluntary incentive structure of the exclusivity has
impacted on the pharmaceutical industry’s efforts to obtain the
exclusivity and how the rule has been used to delay generic
entries for the exclusivity period. METHODS: By using 63 drugs
whose patent expired between 1999 and 2003, obtained from
the FDA, several descriptive analyses were performed. The per-
centage of drugs with pediatric exclusivity was described by
several important factors, especially focusing on main use of the
drugs. Next, all the drugs were divided into two groups—drugs
with exclusivity vs. no exclusivity—and then generic competition
degree was presented by each group for two years following the
initial patent expiration of each drug. RESULTS: A bigger ﬁrm
was good at ﬁling the exclusivity that needs additional clinical
study (p < 0.05). The competition level in each drug’s therapeu-
tic class was positively associated with having the exclusivity.
The drugs with exclusivities were more likely to treat chronic
conditions that include many blockbuster drugs. The ﬁrms have
applied for pediatric extension over the drugs with larger market
size (p < 0.01). For pediatric exclusivity group, there were no
generic competitors until six months and then there was a dra-
matic increase of generic entries after the exclusivity expired
whereas no-pediatric group didn’t show notable increasing trend
during the observation period. CONCLUSION: The market size
of a drug was the most important factor to acquire the pediatric
exclusivity that has been a tool for an originator ﬁrm to delay
generic competition. It implies the incentive structure based on
willingness of industry has not always achieved the primary goal
of “safety of children”.
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OBJECTIVES: Differences between metropolitan and non-
metropolitan setting in the management of chronic conditions 
in patients 55 to 64 years of age can result in higher morbidity
rates in non-metropolitan areas. We will look at the association
between the geographic setting and indicators of care manage-
ment for visits in this population. METHODS: Data from the
National Ambulatory Medical Care and National Hospital
Ambulatory Medical Care (outpatient department) surveys were
combined for years 2001 to 2004. NAMCS and NHAMCS
collect visit data from medical records of randomly selected
physician ofﬁces, hospital outpatient departments, and hospital
emergency departments during randomly selected time periods
through the year. A metropolitan area is an urban area with a
core population of at least 50,000. Visit data were weighted by
the inverse of selection probability and used to provide annual
average estimates. Visits having diagnoses codes for hyperten-
sion, diabetes, COPD, heart disease, stroke, and cancer were
selected based on the ICD-9-CM codes. Number of chronic dis-
eases, medications mentioned, therapeutic and preventive ser-
vices performed, and diagnostic procedures ordered per visit
were compared between metropolitan and non-metropolitan set-
tings. SUDAAN software was used to develop a Poison regres-
sion model to perform the comparisons. Source of payment,
gender, and race for patients were included in the model as
covariates. The effect of the number of previous visits on the out-
comes will be examined in future. RESULTS: Although rural
visits had a higher number of chronic conditions (1.14 vs. 1.11,
p < 0.05), they had a smaller number of therapeutic and pre-
ventive services performed per visit (1.22 vs. 2.73, p < 0.01) and
had a lower number of diagnostic and screening procedures
ordered per visit (2.61 vs. 3.04, p < 0.05). CONCLUSION: The
differences in care management in the years preceding Medicare
eligibility could have implications for utilization of services once
this population enrolls in Medicare.
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OBJECTIVES: The use and awareness of herbal medicines has
been on the rise. Although most of these products are over the
counter (OTC), it is less known how often they are recom-
mended during ofﬁce-based physician visits. Purpose: The objec-
tive of this study was to investigate the trends in prescribing of
herbal medicines in the ambulatory medical setting in the U.S.
METHODS: This study was a retrospective analysis of the
National Ambulatory Medical Care Survey (NAMCS) and 
